I forbindelse med dosisjusteringsundersøgelserne hos børn underbygger de farmakokinetiske data for Azomyr smeltetabletter imidlertid brugen af 2, 5 mg dosen til børn i alderen 6 til 11 år.
Azomyr 2.5 mg tablets has not been evaluated in paediatric patients however in conjunction with the dose finding studies in paediatrics, the pharmacokinetics data for Azomyr orodispersible tablets supports the use of the 2.5 mg dose in paediatric patients 6 to 11 years of age.